RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study

Blood

Volumn 90, Issue 5, 1997, Pages 2041-2046

  Adams Graves, Patricia ^a   Kedar, Amos ^b   Koshy, Mabel ^b   Steinberg, Martin ^b   Veith, Robert ^b   Ward, Daniel ^b   Crawford, Rebekah ^b   Edwards, Suzanne ^b   Bustrack, James ^b   Emanuele, Martin ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

POLOXAMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD RHEOLOGY; BLOOD VESSEL OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS;

EID: 0030930198     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.2041     Document Type: Article

References (43)

1. Serjeant GR: Sickle Cell Disease. New York, NY, Oxford University Press, 1992
2. Benjamin LJ: Convention and experimental approaches to the management of acute vaso-occlusive pain (painful crises), in Mankad VN, Moore RB (eds): Sickle Cell Disease, Pathophysiology, Diagnosis, and Management. Westport, CT, Praeger Publishers, 1992, p 248
3. Ballas SK: The sickle cell painful crisis in adults: Phases and objective signs. Hemoglobin 19:323, 1995
4. Shapiro BS, Ballas SK: The acute painful episode, in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY, Raven, 531, 1994
5. Ballas SK: Neurobiology and treatment of pain, in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY, Raven, 745, 1994
6. Benjamin LJ, Berkowitz LR, Orringer E, Mankad VN, Prasad AS, Lewkow LM, Chillar RK, Peterson CM: A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood 67:1442, 1986
7. Cooperative Urea Trials Group: Clinical trials of therapy for sickle cell vasoocclusive crises. JAMA 228:1120, 1974
8. Cooperative Urea Trials Group: Treatment of sickle cell crises with urea in invert sugar. A controlled trial. JAMA 228:1125, 1974
9. Harkness DR, Roth S: Clinical evaluation of cyanate in sickle cell anemia. Prog Hematol 9:157, 1975
10. Peterson CM, Tsairis P, Ohnishi A, Lu YS, Grady R: Sodium cyanate induced polyneuropathy in patients with sickle cell disease. Ann Intern Med 81:152, 1974
11. Griffin TC, McIntire D, Buchanan GR: High dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 330:733, 1994
12. Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL: Bone marrow transplantation for sickle cell disease: A study of parents' decisions. N Engl J Med 325:1349, 1991
13. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, Storb R, and Sullivan KM: Bone marrow transplantation for sickle cell disease. N Engl J Med 335:369, 1996
14. Platt OS, Guinan EC: Bone marrow transplantation in sickle cell anemia - the dilemma of choice. N Engl J Med 335:426, 1996
15. Rodgers GP, Dover GJ, Nobuhiro U, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73, 1993
16. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF: Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol 19:74, 1992
17. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai S, Vichinsky EP, Olivieri NF: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 328:8, 1993
18. Fibach E, Prasanna P, Rodgers GP, Samid D: Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia. Blood 82:2203, 1993
19. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PFA, Orringer EP, Phillips G, Platt OS, Thomas GH: Hydroxurea effects on hemoglobin F production in patients with sickle cell anemia. Blood 79:2555, 1992
20. Dover J, Bruisilow S, Charache S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenybutyrate. Blood 84:339, 1994
21. Ballas S, Dover GJ, Charache S: Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 32:104, 1991
22. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Ecken SV, McMahan RP, Bonds DR: Multicenter study of hydroxyurea in sickle cell anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317, 1995
23. Charache S, Dover GJ, Moyer MA, Moore JW: Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69:109, 1987
24. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH: Erythrocyte adherence to endothelium in sickle cell anemia. A possible determinant of disease severity. N Engl J Med 302:992, 1980
25. + sickle reticulocytes to endothelial cells. Blood 80:2634, 1992
26. Wick TM, Moake JL, Udden MM, McIntire LV: Unsually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hematol 42:284, 1993
27. Swerlick RA, Eckman JR, Kumar A, Jeitler M, WicK TM: 4β1-Integrin expression on sickle reticulocytes: Vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 82:1891, 1993
28. Gee BE, Platt OS: Sickle reticulocytes adhere to VCAM-1. Blood 85:268, 1995
29. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vasoocclusion. Blood 81:2137, 1993
30. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82:3548, 1993
31. Hunter RL, Papadea C, Gallagher CJ, Finlayson DC, Check IJ: Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188. Thromb Haemost 63:6, 1990
32. Grover FL, Heron MW, Newman MM, Paton BC: Effect of a nonionic surface-active agent on blood viscosity and platelet adhesiveness. Circulation 39 and 40:I249, 1969 (suppl I)
33. Grover FL, Kahn RS, Heron MW, Paton BC: A nonionic surfactant and blood viscosity. Experimental observations. Arch Surg 106:307, 1973
34. Robinson KA, Hunter RL, Stack JE, Hearn JA, Apkarian RP, Roubin GS: Inhibition of coronary arterial thrombosis in swine by infusion of poloxamer 188. J Inv Cardiol 2:9, 1990
35. Papadea C, Hunter R: Effect of RheothRx® Copolymer on blood viscosity related to fibrin(ogen) concentration. FASEB J 21988:A384, 1988
36. Meiselman J, Nash GB, Sowemimo-Coker SO, Stuart J, Toth K, Wenby RB: Hemorheological effect of nonionic copolymer surfactants. Clin Hemorheol 11:701, 1991 (abstr)
37. Carter C, Fisher TC, Hamai H, Johnson CS, Meiselman HJ, Nash GB, et al: Haemorheological effects of a nonionic copolymer surfactant (poloxamer 188). Clin Hemorheol 12:109, 1992
38. Benner KU, Gaehtgens P, Frede KE: Aggregation of human red blood cells (RBC) and platelets and its reversal by a surface-active substance (Pluronic F68). Bibl Anat 12:208, 1973
39. Gaehtgens P, Benner KU: Disaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and hemolysis. Acta Haematol 53:82, 1975
40. Toth K, Sowemimo-Coker SO, Wenby RB, Meiselman HJ: Effects of poloxamer 188 (RheothRx®) on polymer-induced red blood cell aggregation. Clin Hemorheol 11:755, 1991 (abstr)
41. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ: Categorical data analysis, in Berry DA (ed): Statistical Methodology in the Pharmaceutical Sciences. New York, NY, Dekker, 1990, p 389
42. Yusef S: For the Collaborative Organization for RheothRx Evaluation trialists. Circulation 22:I-24, 1995 (suppl 1)
43. Weaver W, Douglas: For the Myocardial Infarction Study Group. Circulation 22:I-24, 1995 (suppl 1)